Principle and Application of CAR-T Cell Therapy for Cancer

Research Article
Open access

Principle and Application of CAR-T Cell Therapy for Cancer

Ruonan He 1 , Yingqi Huang 2 , Ruobing Qian 3*
  • 1 College of Plant Sciences, Jilin university, Changchun, China    
  • 2 College biological science, University of Edinburgh, Edinburgh, UK    
  • 3 College of Life Science, Ritsumeikan University, Kusatsushi,Siga. Japan    
  • *corresponding author sj0095xs@ed.ritsumei.ac.jp
Published on 28 April 2023 | https://doi.org/10.54254/2753-8818/4/20220646
TNS Vol.4
ISSN (Print): 2753-8826
ISSN (Online): 2753-8818
ISBN (Print): 978-1-915371-27-0
ISBN (Online): 978-1-915371-28-7

Abstract

CAR-T therapy is a High-profile technology in cancer immunotherapy, which has developed rapidly and has made great achievements in the treatment of hematologic tumors. Its therapeutic principle makes CAR-T cell therapy a great advantage in the treatment of relapsed refractory chronic lymphocytic leukemia. However, CAR-T cell therapy still faces many problems, such as side effects, off-target effects, and the lack of specific antigen deficiency on the surface of solid tumors and so on. At present, it is an important research direction to reduce the impact of side effects on patients and its application in solid tumors. This paper focused on the principles and application of involved in CAR-T cell therapy, and the side effects brought by CAR-T therapy were sorted out. Finally, the further development of CAR-T therapy has prospected

Keywords:

immunotherapy, cancer, chimeric antigen receptor, the CAR-T therapy

He,R.;Huang,Y.;Qian,R. (2023). Principle and Application of CAR-T Cell Therapy for Cancer. Theoretical and Natural Science,4,545-553.
Export citation

References

[1]. International Agency for Research on Cancer: All cancers-CANCER FACT SHEETS

[2]. D.L. Porter, W.T. Hwang, et al. CART cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015 Sep 2;7(303):303ra139.

[3]. B. Fang, H. Kai, et al. Clinical analysis of 10 cases of refractory and recurrent B-cell tumors treated with anti-CD19 CAR-T cells, 2018 Jun; 39(6): 454-459

[4]. C. Robert Sterner and Rosalie M. Sterner, CAR-T cell therapy: current limitations and potential strategies, Blood Cancer J. 2021 Apr; 11(4): 69

[5]. G. Gross, et al.1989. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. PNAS, 86(24), pp.10024-10028

[6]. Z, Eshar., et al. 1993. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. PNAS, 90(2), pp.720-724

[7]. U. Altenshmidt, D. Moritz, and B.Groner, , 1997. Specific cytotoxic T lymphocytes in gene therapy. J. M.M, 75(4), pp.259-266

[8]. A. Filley, et al.2018. CART Immunotherapy: Development, Success, and Translation to Malignant Gliomas and Other Solid Tumors. Frontiers in Oncology, 8.

[9]. D. Lenschow. et al. 1996. CD28 SYSTEM OF T CELL COSTIMULATION. Annual Review of Immunology, 14(1), pp.233-258.

[10]. R. Simoneaux, 2020. KTE-X19 CAR T Cells in Relapsed Mantle Cell Lymphoma. Oncology Times, 42(S10), pp.1,9-10

[11]. S. van der Stegen, et al.2015. The pharmacology of second-generation chimeric antigen receptors. Nature Reviews Drug Discovery, 14(7), pp.499-509

[12]. M. Pasquini, et al.2019. Post-Marketing Use Outcomes of an Anti-CD19 CART, Axi-Cel, for the Treatment of LBCL in the US. Blood, 134, pp.764-764

[13]. R. J. Buka, and A. J. Kansagra (2020). CAR T-cell therapy: insight into current and future applications / Richard J. Buka, Ankit J. Kansagra. Basel: S. Karger

[14]. Who.int.2022. <https://www.who.int/zh/news-room/fact-sheets/detail/cancer>

[15]. Y.Q. Xu. CAR-T and CAR-T in the treatment of solid tumors - prospective outlook and practical issues [C] 2015

[16]. S.J. Wang. Review of CAR-T therapy technology development. Technology and Innovation, 2018(15):4

[17]. X.R. Li, et al. Research progress of CAR-T therapy in the treatment of tumor immune escape. Modern medical oncology, 2021, 29(15):4

[18]. M. Lin, et al. A study on health insurance payment policies for CAR-T cell therapy products: an empirical analysis based on Medicare in the United States. China Journal of New Drugs, 2022, 31(15):6

Cite this article

He,R.;Huang,Y.;Qian,R. (2023). Principle and Application of CAR-T Cell Therapy for Cancer. Theoretical and Natural Science,4,545-553.

Data availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

Disclaimer/Publisher's Note

The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

About volume

Volume title: Proceedings of the 2nd International Conference on Biological Engineering and Medical Science (ICBioMed 2022), Part II

ISBN：978-1-915371-27-0(Print) / 978-1-915371-28-7(Online)
Editor：Gary Royle, Steven M. Lipkin
Conference website: http://www.icbiomed.org
Conference date: 7 November 2022
Series: Theoretical and Natural Science
Volume number: Vol.4
ISSN：2753-8818(Print) / 2753-8826(Online)

© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open access policy for details).

References

[1]. International Agency for Research on Cancer: All cancers-CANCER FACT SHEETS

[2]. D.L. Porter, W.T. Hwang, et al. CART cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015 Sep 2;7(303):303ra139.

[3]. B. Fang, H. Kai, et al. Clinical analysis of 10 cases of refractory and recurrent B-cell tumors treated with anti-CD19 CAR-T cells, 2018 Jun; 39(6): 454-459

[4]. C. Robert Sterner and Rosalie M. Sterner, CAR-T cell therapy: current limitations and potential strategies, Blood Cancer J. 2021 Apr; 11(4): 69

[5]. G. Gross, et al.1989. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. PNAS, 86(24), pp.10024-10028

[6]. Z, Eshar., et al. 1993. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. PNAS, 90(2), pp.720-724

[7]. U. Altenshmidt, D. Moritz, and B.Groner, , 1997. Specific cytotoxic T lymphocytes in gene therapy. J. M.M, 75(4), pp.259-266

[8]. A. Filley, et al.2018. CART Immunotherapy: Development, Success, and Translation to Malignant Gliomas and Other Solid Tumors. Frontiers in Oncology, 8.

[9]. D. Lenschow. et al. 1996. CD28 SYSTEM OF T CELL COSTIMULATION. Annual Review of Immunology, 14(1), pp.233-258.

[10]. R. Simoneaux, 2020. KTE-X19 CAR T Cells in Relapsed Mantle Cell Lymphoma. Oncology Times, 42(S10), pp.1,9-10

[11]. S. van der Stegen, et al.2015. The pharmacology of second-generation chimeric antigen receptors. Nature Reviews Drug Discovery, 14(7), pp.499-509

[12]. M. Pasquini, et al.2019. Post-Marketing Use Outcomes of an Anti-CD19 CART, Axi-Cel, for the Treatment of LBCL in the US. Blood, 134, pp.764-764

[13]. R. J. Buka, and A. J. Kansagra (2020). CAR T-cell therapy: insight into current and future applications / Richard J. Buka, Ankit J. Kansagra. Basel: S. Karger

[14]. Who.int.2022. <https://www.who.int/zh/news-room/fact-sheets/detail/cancer>

[15]. Y.Q. Xu. CAR-T and CAR-T in the treatment of solid tumors - prospective outlook and practical issues [C] 2015

[16]. S.J. Wang. Review of CAR-T therapy technology development. Technology and Innovation, 2018(15):4

[17]. X.R. Li, et al. Research progress of CAR-T therapy in the treatment of tumor immune escape. Modern medical oncology, 2021, 29(15):4

[18]. M. Lin, et al. A study on health insurance payment policies for CAR-T cell therapy products: an empirical analysis based on Medicare in the United States. China Journal of New Drugs, 2022, 31(15):6

For authors
Guide for authors Policies for authors Aims and scope Subscription Open access policy
For editors
Policies for editors Editorial board
For reviewers
Policies for reviewers Privacy policy

Cookies are used by this site.
Copyright © 2024 EWA Publishing, its licensors, and contributors. All rights reserved, including text and data mining, AI training, and similar technologies.